Novo Nordisk was arguably the NVIDIA of pharma stocks in 2023. Ozempic / Wegovy have become all the rage in the treatment of diabetes and obesity. Unlike the pandemic and its benefit for Pfizer, these diseases aren’t fads that are about to disappear. Does that mean that the drugs are guaranteed to continue being a success? Or should investors be worried about competition?

This content is for Premium and Premium – Annual members only.
Login Join Now